Quebec, New Brunswick, Newfoundland, Nova Scotia and Manitoba join Alberta, Saskatchewan, in adding Knight's PROBUPHINE® to their provincial drug plans in the fight against the opioid crisis
- PROBUPHINE® is also listed for reimbursement through the Non-Insured Health Benefit (NIHB) and Veteran Affairs Canada drug plans
- PROBUPHINE® is the first and only buprenorphine implant approved in Canada for the long-term maintenance management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support.1